CytoAgents’ is currently developing CTO1681 in indications with high unmet need
Our novel drug, CTO1681, has the potential to both prevent and treat CRS. We are developing specific formulations to provide not only the best delivery mechanism for each indication, but also our drug has the potential to both treat and prevent Cytokine Release Syndrome.
CAR T-Cell therapy is a revolutionary and highly effective therapy developed to treat cancer. Unfortunately, up to 70% of patients who receive the treatment will experience CRS, which remains a roadblock to broader adoption of this life-saving treatment.
Over 7% of adults are affected by Atopic Dermatitis, which is characterized by a cytokine induced skin inflammation and irritation. Cytokine release is also known to aid the pathogenesis of AD.
Cytokines are released during the body’s natural process of repairing itself after a traumatic brain injury. When CRS occurs in this context, it can exacerbate the existing damage and create more in its wake. 89% of Traumatic Brain Injuries result in Organ Dysfunction caused by CRS.
Cytokine Release Syndrome (CRS) has been associated with high mortality in severe COVID-19 patients suffering from Acute Respiratory Distress Syndrome (ARDS), coagulation, and multi-organ dysfunctions.
CTO1681 is applicable to multiple therapeutic areas.
Phase 1 human safety trials have been completed.
CTO1681 reduces the Cytokine Release Syndrome triggered by CAR T-Cell Therapy while maintaining proper immune function. By combining a demonstrated, broad mechanism of action to modulate cytokine production with a well-established safety record, it is positioned to become a new best practice in medicine.